|
|
Post by bernstein on Oct 11, 2017 15:42:36 GMT
Market Cap $17 M / Cash $11.8 M / 4 Marketed Products one of them Natesto targeting $2 BILLION Market / Shares Out only 4.22 M ..After doing my dd i can say for sure this unknown stock is a brutal gift at this price .This low float stock should be valued at minimum $120-150 Million (~$30-35 per share ) right now for their marketed products .GL Market Cap : $17 Million Cash $11.8 Million Price $4 Shares Out 4.22 Million Presentation aytubio.com/downloads/Aytu-Corporate-Overview.pdfFact Sheet aytubio.com/downloads/Aytu-Corporate-Fact-Sheet.pdfMarketed Products:
•Natesto–testosterone nasal gel indicated for hypogonadism ($2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)
•MiOXSYS–in vitro device for male infertility ($825 million International market ,30 million men impacted in U.S.)
•Fiera–pre-intimacy device to increase sexual desire and arousal in women (53 million women in the U.S. with sexual concerns)
•ProstaScint–imaging agent for prostate cancerAytu BioScience (AYTU) Stock: Why This Thing Can Grow Legs! cnafinance.com/aytu-bioscience-aytud-aytu-stock-why-this-thing-can-grow-legs/16622Aytu BioScience, Inc.(OTCMKTS: AYTU) is a stock that we've covered in great detail as of late, and for good reason. The company is in the prime position to take charge of a massive industry with hundreds of millions if not billions of dollars in potential revenue. Today, we'll get into one of the many reasons that we're so bullish with regard to AYTU, a reason that can be summed up in a single word, Natesto . |
|
|
|
Post by omstem on Oct 11, 2017 16:36:55 GMT
Thank you Bernstein:
Looks pretty interesting. I am going to follow it and start a small position. the 52 week High was a good number around $77.00. Even if it reaches 50% of the 52 week high from the current levels that will still be a great return. But it is traded on OTC and very low volumes. That could be a concern.
|
|
|
|
Post by bernstein on Oct 11, 2017 20:51:30 GMT
Uplisting to Nasdaq is one of their upcoming milestones ...   |
|
|
|
Post by lcd on Oct 11, 2017 21:20:05 GMT
Thank you Bernstein: Looks pretty interesting. I am going to follow it and start a small position. the 52 week High was a good number around $77.00. Even if it reaches 50% of the 52 week high from the current levels that will still be a great return. But it is traded on OTC and very low volumes. That could be a concern. At this time two years ago, the pps was equivalent to $1000 so the company has been headed in the wrong direction. Bernstein, do you know why this company's pps has plummeted so much over the past two years? It looks like Natesto came on the market just over one year ago and sales have been flat but they are projecting exponential growth in Q4. It is definitely worth investigating further. Thanks for sharing Bernstein. |
|
|
|
Post by bernstein on Oct 12, 2017 12:17:51 GMT
I find nothing but maybe it has to do with the reverse split they did . The real BIG NEWS for AYTU and their testosterone drug Natesto is this below which means they have the potential to capture a very large market share in this $2 BILLION market . cnafinance.com/aytu-bioscience-aytud-aytu-stock-why-this-thing-can-grow-legs/16622The Doors To Massive Potential Have Swung Wide Open
As if there already wasn't massive potential surrounding NATESTO, the flood gates may open soon as the competition has largely been cleared off of the playing field. That happened relatively recently when Acrux and Eli Lilly ended their relationship surrounding the testosterone product known as Axiron, a TRT applied under the arm.
It all started back in 2010 when Acrux and Eli Lilly entered into a license agreement surrounding Axiron. As a result of the deal, there would be $335 million plus potential royalties up for grabs. However, early this month, in fact on September 6th, it was announced that both companies have reached an agreement to terminate the license agreement.
While this may not seem like a big deal at first glance, it's massive. You see, Axiron was one of the only competing drugs that was marketed on a large scale. However, for this marketing to take place, it had to happen with the help of Eli Lilly. Since the relationship has been split, the marketing is no longer in place. As a result, AYTU has an open playing field with NATESTO, giving it the opportunity to tackle the market in a big way.
NATESTO Is Black Box Free
While there are many advantages that we see in NATESTO over other testosterone replacement therapies, there's one key advantage that really strikes us. That is the fact that the product is the only TRT (Testosterone Replacement Therapy) currently on the market that's not only effective, but comes with no black box warnings.
For those of you who don't know, black box warnings are among the strictest warnings that the FDA imposes on labeling of prescription drugs. These warnings are only used when there is reasonable evidence of an association of a serious hazard with the drug in question. While other TRTs on the market have various black box warnings associated with the risk of a man transferring testosterone gel to his female partner or child, NATESTO is black box warning free; making it one of the safest, if not the safest option for testosterone replacement.
The Bottom Line The bottom line here is that AYTU has a tremendous opportunity and through this opportunity, poses a potentially incredible opportunity for investors themselves. Looking at NATESTO, it's clear that not only is this drug the safest option, it is likely to become the first option. With the sales force nearing the ability to hit the ground running and an incredible management team behind them, I believe that 2018 will be the year for AYTU; and we haven't even touched on Fiera or Mioxys yet.... those are topics for another day! |
|
|
|
Post by bernstein on Oct 13, 2017 19:24:58 GMT
|
|
|
|
Post by omstem on Oct 13, 2017 20:42:26 GMT
Thank you very much Bernstein:
I totally agree with your assessment that Black Box free nature of their lead drug is a huge positive.
Apart from the Eli Lilly dropping Axiron and Mylan's controversy with EpiPen, the field seem to be wide open.
I am going to initiate a position after researching the reasons for several Reverse Splits and huge drop in the PPS over last few years.
Thanks again for sharing.
|
|
|
|
Post by bernstein on Oct 17, 2017 15:13:49 GMT
i sent an email to the company asking about Nasdaq listing and potential outlicensing or co-promotion of Natesto below is the answer from Josh disbrow (ceo) . And there was more good news for AYTU because Antares (ATRS) who has also a Testosterone Product close to Approval got a FDA letter so Approval is may unlikely on october 20 link to full story see below . Hi xxxxxx Thanks for your email. We now have a strong cash balance following our $11.8M private placement that closed on August 15th. We expect to uplist to NASDAQ in the very near term, and that process is well underway. We have initiated substantial IR over the last 6 weeks and, with the registration of the shares recently placed, we expect to see a significant increase in our market float and trading volume. We have a strong sales team of 35 sales representatives calling on the top 7,000 TRT prescribers. That said, we are always open to exploring relationships through which we can further enhance our presence. That said, prescriptions for Natesto continue to reach all time high levels. We are very pleased with the progress. Thanks for your interest in AYTU. Best, Josh With Antares Pharma’s (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary? cnafinance.com/with-antares-pharmas-atrs-xyosted-doa-is-aytu-bioscience-aytu-the-beneficiary/16792 |
|
|
|
Post by bernstein on Oct 18, 2017 13:18:00 GMT
|
|
|
|
Post by JHam on Oct 18, 2017 15:31:29 GMT
Jeezus. Too late open a position now...maybe... |
|
|
|
Post by omstem on Oct 21, 2017 1:27:49 GMT
Bernstein:
Thank you very much for your recommendation. I have initiated a position yesterday. It went down today. But I am not worried. They are now on NASDAQ. The current volume is better than their previous daily average volume. This company will be recognized. I may add more if goes down further. I have ignored some companies in the past thinking that they were already high and they went even higher. I sure do understand that not all stories are the same. But in this case I have good feeling that the current PPS is ALMOST AT THE BOTTOM IF NOT THE DEEPEST BOTTOM. Their listing on NASDAQ is another positive that was previously a red mark in my DD. Thanks again for recommending it.
|
|
